首页> 美国卫生研究院文献>OncoTargets and therapy >Emerging role of long non-coding RNAs in cisplatin resistance
【2h】

Emerging role of long non-coding RNAs in cisplatin resistance

机译:长非编码RNA在顺铂耐药中的新兴作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Cisplatin (CDDP) is one of the most commonly used chemotherapy drugs for the treatment of various cancers. Although platinum-based therapies are highly efficacious against rapidly proliferating malignant tumors, the development of CDDP resistance results in significant relapse as well as decreased overall survival rates, which is a significant obstacle in CDDP-based cancer therapy. Long non-coding RNAs (lncRNAs) are involved in cancer development and progression by the regulation of processes related to chromatin remodeling, transcription, and posttranscriptional processing. Emerging evidence has recently highlighted the roles of lncRNAs in the development of CDDP resistance. In this review, we discuss the roles and mechanisms of lncRNAs in CDDP chemoresistance, including changes in cellular uptake or efflux of a drug, intracellular detoxification, DNA repair, apoptosis, autophagy, cell stemness, and the related signaling pathways, aiming to provide potential lncRNA-targeted strategies for overcoming drug resistance in cancer therapy.
机译:顺铂(CDDP)是用于治疗各种癌症的最常用化疗药物之一。尽管基于铂的疗法对迅速扩散的恶性肿瘤非常有效,但CDDP耐药性的发展会导致明显的复发以及降低的总生存率,这是基于CDDP的癌症疗法的重要障碍。长非编码RNA(lncRNA)通过调节与染色质重塑,转录和转录后加工有关的过程参与癌症的发展和进程。最近出现的证据突出了lncRNA在CDDP抗性发展中的作用。在这篇综述中,我们讨论了lncRNA在CDDP化学抗性中的作用和机制,包括细胞摄取或排出药物的变化,细胞内排毒,DNA修复,凋亡,自噬,细胞干性以及相关的信号传导途径,旨在提供潜在的潜力。在癌症治疗中克服耐药性的lncRNA靶向策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号